X0609 4 2026-09-17 0001674416 CRISPR Therapeutics AG CRSP 0001613867 Behbahani Ali false 2855 SAND HILL ROAD MENLO PARK CA 94025 true false false false false Common Shares 2026-09-17 4 M false 30000 14 A 30316 D Common Shares 2026-09-17 4 S false 13679 57.0901 D 16637 D Common Shares 29 I See Note 2 Stock Option (Right to Buy) 14 2026-09-17 4 M false 30000 0 D 2026-10-18 Common Shares 30000 0 D The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.97 to $57.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person is the trustee of The Ali Behbahani Revocable Trust Dated June 26, 2015 (the "Behbahani Trust"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, of such portion of the Common Shares of the Issuer held by the Behbahani Trust in which the Reporting Person has no pecuniary interest. This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. /s/ Zachary Bambach, attorney-in-fact 2026-09-21